Galectin Therapeutics Inc.
GALT
$1.37
$0.032.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.33% | -0.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.08% | -19.71% | |||
| Operating Income | -37.08% | 19.71% | |||
| Income Before Tax | -6.66% | 9.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.66% | 9.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.66% | 9.30% | |||
| EBIT | -37.08% | 19.71% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -6.26% | 9.71% | |||
| Normalized Basic EPS | -5.86% | 9.34% | |||
| EPS Diluted | -6.26% | 9.80% | |||
| Normalized Diluted EPS | -5.86% | 9.34% | |||
| Average Basic Shares Outstanding | 0.75% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.75% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||